Jane L. Mendillo - 26 Feb 2026 Form 4 Insider Report for Generate Biomedicines, Inc. (GENB)

Role
Director
Signature
/s/ Michael Wolf, Attorney-in-Fact
Issuer symbol
GENB
Transactions as of
26 Feb 2026
Net transactions value
+$24,000
Form type
4
Filing time
02 Mar 2026, 17:47:29 UTC
Previous filing
20 Feb 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Mendillo Jane L Director GENERATE BIOMEDICINES, INC., 101 SOUTH STREET, SUITE 900, SOMERVILLE /s/ Michael Wolf, Attorney-in-Fact 02 Mar 2026 0001672424

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GENB Common Stock Purchase $24,000 +1,500 $16.00 1,500 02 Mar 2026 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GENB Stock Option (Right to Buy) Award $0 +29,561 $0.000000 29,561 26 Feb 2026 Common Stock 29,561 $16.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date.